Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 226 participants.
Also called NCT01743001
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 226 participants
- Sponsor
- Registry
-
NCT01743001
-
- Other papers using this trial's data
- Evaluation of Macitentan in Patients With Eisenmenger Syndrome
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Bulgaria, Chile, China, France, Germany, Greece, Israel, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Russia, Serbia, Spain, Türkiye, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT01743001. Randomized; quadruple masking; primary purpose treatment. Start 2013-05-21 (actual); primary completion 2016-12-01 (actual). Results posted on 2018-01-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
- Acronym
- MAESTRO
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Macitentan 10 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Actelion
Record details
- Record id
cardio:ct-nct01743001- Content hash
99ba44afa3e59b426c4c166fee04b8d04f8ff3b0e45c01efd72e7ac6c0832524